Literature DB >> 2262800

Modification of the 8 drugs in 1 day regimen: feasibility of substitution of other agents.

K W Chan1, C J Fryer, P Steinbok.   

Abstract

Six children (ages 2 to 14 years) with recurrent or poor risk primary brain tumors were treated with the '8 drugs in 1 day' chemotherapy regimen. As renal function deteriorated (median after five cycles), carboplatin was substituted in place of cisplatin at a median dose of 300 mg/m2 as a one hour infusion at hour three. Four patients also had their lomustine deleted and replaced by etoposide 100 mg/m2 at hour four. Compared to earlier cycles of chemotherapy, there was a moderate increase in transfusion requirement (especially platelets) but the incidences of fever and neutropenia were unchanged. Glomerular function as measured by nuclear glomerular filtration rate (GFR) remained unchanged or improved at the end of therapy. The severity of nausea and vomiting after substitution was markedly improved. Four of the six patients are still in complete remission 19 to 41 months after diagnosis or recurrence. It is feasible to substitute carboplatin and etoposide into the '8 drugs in 1 day' regimen when extramedullary toxicity is found.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2262800     DOI: 10.1007/bf02427836

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

1.  Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report.

Authors:  P S Gaynon; L J Ettinger; D Moel; S E Siegel; E S Baum; W Krivit; G D Hammond
Journal:  Cancer Treat Rep       Date:  1987-11

2.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

3.  Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

Authors:  M J Egorin; D A Van Echo; S J Tipping; E A Olman; M Y Whitacre; B W Thompson; J Aisner
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

4.  Eight drugs in one day chemotherapy in children with brain tumors: a critical toxicity appraisal.

Authors:  J R Geyer; T W Pendergrass; J M Milstein; W A Bleyer
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

5.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

6.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

7.  Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.

Authors:  J H Edmonson; G W McCormack; J E Krook; H J Long; J A Jefferies; R L Richardson
Journal:  Cancer Treat Rep       Date:  1987-02

8.  Carboplatin and recurrent childhood brain tumors.

Authors:  J C Allen; R Walker; E Luks; M Jennings; S Barfoot; C Tan
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

9.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

Authors:  W Ross; T Rowe; B Glisson; J Yalowich; L Liu
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Interaction of etoposide and cisplatin in an in vitro tumor model.

Authors:  R E Durand; J H Goldie
Journal:  Cancer Treat Rep       Date:  1987 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.